VMD · Viemed Healthcare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.41M | - | $71.91M | $63.06M | $59.13M | - | $58.00M | $54.97M | $50.59M | - |
| Cost of Revenue | $32.59M | - | $30.57M | $26.32M | $25.85M | - | $23.63M | $22.07M | $20.79M | - |
| Gross Profit | $42.83M | - | $41.34M | $36.73M | $33.28M | - | $34.37M | $32.89M | $29.80M | - |
| R&D | $579.0K | - | $775.0K | $847.0K | $797.0K | - | $757.0K | $758.0K | $750.0K | - |
| SG&A | $34.79M | - | $31.92M | $28.80M | $28.43M | - | $26.67M | $26.50M | $24.81M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $7.62M | - | $397.0K | $353.0K | $6.61M | - | $419.0K | $298.0K | $6.29M | - |
| Operating Income | $4.30M | - | $5.64M | $5.09M | $3.84M | - | $5.63M | $3.62M | $2.20M | - |
| Interest Expense | $179.0K | - | - | - | - | - | - | - | - | - |
| Income Tax | $1.28M | - | $1.53M | $1.71M | $952.0K | - | $1.59M | $768.0K | $518.0K | - |
| Net Income | $2.58M | - | $3.51M | $3.16M | $2.63M | - | $3.88M | $1.47M | $1.60M | - |
| EPS - Basic | $0.07 | - | $0.09 | $0.08 | $0.07 | - | $0.10 | $0.04 | $0.04 | - |
| EPS - Diluted | $0.06 | - | $0.09 | $0.08 | $0.06 | - | $0.10 | $0.04 | $0.04 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.76M | $13.50M | $11.12M | $20.02M | $10.16M | $17.54M | $11.35M | $8.81M | $7.31M | $12.84M |
| Accounts Receivable | $31.18M | $25.59M | $27.41M | $26.55M | $26.79M | $24.91M | $27.05M | $27.06M | $24.48M | $18.45M |
| Inventory | $5.18M | $5.05M | $5.27M | $4.32M | $4.51M | $4.32M | $4.31M | $4.42M | $4.35M | $4.63M |
| Accounts Payable | $8.57M | $7.33M | $8.67M | $8.25M | $7.94M | $5.32M | $6.01M | $6.33M | $5.80M | $4.18M |
| Current Assets | $49.81M | $48.49M | $49.98M | $55.29M | $49.12M | $52.88M | $47.70M | $44.98M | $38.62M | $38.37M |
| Total Assets | $197.36M | $199.15M | $202.36M | $184.60M | $178.08M | $177.07M | $169.53M | $163.95M | $154.88M | $154.90M |
| Current Liabilities | $40.71M | $41.06M | $44.19M | $37.27M | $35.49M | $37.33M | $36.44M | $31.48M | $30.12M | $32.12M |
| Long-term Debt | $8.33M | $11.29M | $19.59M | $3.46M | $3.53M | $3.59M | $3.65M | $8.71M | $5.91M | $6.00M |
| Total Liabilities | $51.56M | $55.63M | $66.86M | $42.98M | $41.33M | $43.77M | $42.73M | $42.77M | $38.60M | $41.00M |
| Stockholders' Equity | $143.86M | $141.54M | $133.61M | $139.73M | $134.76M | $131.39M | $124.96M | $119.37M | $116.27M | $113.89M |
| Retained Earnings | $105.47M | $102.89M | $97.25M | $93.84M | $90.73M | $89.69M | $85.38M | $81.59M | $80.14M | $79.50M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.07M | - | - | - | $2.85M | - | - | - | $1.18M | - |
| Investing Cash Flow | ($5.49M) | - | - | - | ($8.53M) | - | - | - | ($5.37M) | - |
| Financing Cash Flow | ($6.33M) | - | - | - | ($1.70M) | - | - | - | ($1.34M) | - |
| CapEx | $6.71M | - | - | - | $15.48M | - | - | - | $6.01M | - |
| Free Cash Flow | $1.36M | - | - | - | ($12.63M) | - | - | - | ($4.83M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 56.8% | - | 57.5% | 58.3% | 56.3% | - | 59.3% | 59.8% | 58.9% | - |
| Operating margin | 5.7% | - | 7.8% | 8.1% | 6.5% | - | 9.7% | 6.6% | 4.4% | - |
| EBITDA margin | 15.8% | - | 8.4% | 8.6% | 17.7% | - | 10.4% | 7.1% | 16.8% | - |
| Net margin | 3.4% | - | 4.9% | 5.0% | 4.4% | - | 6.7% | 2.7% | 3.2% | - |
| Free cash flow margin | 1.8% | - | - | - | -21.4% | - | - | - | -9.5% | - |
| FCF / Net income | 0.53 | - | - | - | -4.81 | - | - | - | -3.01 | - |
| R&D / Revenue | 0.8% | - | 1.1% | 1.3% | 1.3% | - | 1.3% | 1.4% | 1.5% | - |
| SG&A / Revenue | 46.1% | - | 44.4% | 45.7% | 48.1% | - | 46.0% | 48.2% | 49.0% | - |
| Effective tax rate | 33.1% | - | 30.4% | 35.2% | 26.6% | - | 29.1% | 34.3% | 24.4% | - |
| Return on assets | 1.3% | - | 1.7% | 1.7% | 1.5% | - | 2.3% | 0.9% | 1.0% | - |
| Return on equity | 1.8% | - | 2.6% | 2.3% | 1.9% | - | 3.1% | 1.2% | 1.4% | - |
| Return on invested capital | 1.9% | - | 2.6% | 2.3% | 2.0% | - | 3.1% | 1.9% | 1.4% | - |
| Liquidity | ||||||||||
| Current ratio | 1.22 | 1.18 | 1.13 | 1.48 | 1.38 | 1.42 | 1.31 | 1.43 | 1.28 | 1.19 |
| Quick ratio | 1.10 | 1.06 | 1.01 | 1.37 | 1.26 | 1.30 | 1.19 | 1.29 | 1.14 | 1.05 |
| Cash ratio | 0.24 | 0.33 | 0.25 | 0.54 | 0.29 | 0.47 | 0.31 | 0.28 | 0.24 | 0.40 |
| Leverage | ||||||||||
| Debt / Equity | 0.06 | 0.08 | 0.15 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.05 | 0.05 |
| Debt / Assets | 0.04 | 0.06 | 0.10 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.04 | 0.04 |
| Debt / EBITDA | 0.70 | - | 3.24 | 0.64 | 0.34 | - | 0.60 | 2.23 | 0.70 | - |
| Interest coverage | 24.0x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.37 | 1.41 | 1.51 | 1.32 | 1.32 | 1.35 | 1.36 | 1.37 | 1.33 | 1.36 |
| Liabilities / Assets | 0.26 | 0.28 | 0.33 | 0.23 | 0.23 | 0.25 | 0.25 | 0.26 | 0.25 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.38 | - | 0.36 | 0.34 | 0.33 | - | 0.34 | 0.34 | 0.33 | - |
| Inventory turnover | 6.29 | - | 5.80 | 6.09 | 5.73 | - | 5.48 | 4.99 | 4.78 | - |
| Days sales outstanding | 151d | - | 139d | 154d | 165d | - | 170d | 180d | 177d | - |
| Days inventory outstanding | 58d | - | 63d | 60d | 64d | - | 67d | 73d | 76d | - |
| Days payable outstanding | 96d | - | 104d | 114d | 112d | - | 93d | 105d | 102d | - |
| Cash conversion cycle | 113d | - | 99d | 99d | 117d | - | 144d | 148d | 151d | - |
| Valuation | ||||||||||
| P / E | 153.5x | - | 75.4x | 86.4x | 121.3x | - | 73.3x | 163.8x | 235.8x | - |
| P / B | 2.6x | - | 2.1x | 2.0x | 2.2x | - | 2.4x | 2.2x | 3.3x | - |
| P / S | 4.9x | - | 3.8x | 4.5x | 5.1x | - | 5.2x | 4.8x | 7.6x | - |
| EV / EBITDA | 31.2x | - | 46.9x | 49.1x | 28.4x | - | 48.2x | 67.8x | 44.9x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 27.5% | - | 24.0% | 14.7% | 16.9% | - | 17.4% | 26.9% | 27.9% | - |
| Revenue CAGR (3y) | 24.0% | - | 26.2% | 23.7% | 22.4% | - | 25.6% | 26.1% | 21.2% | - |
| Revenue CAGR (5y) | 21.6% | - | 16.5% | 8.0% | 20.0% | - | 27.6% | 28.8% | - | - |
| Gross profit growth (YoY) | 28.7% | - | 20.3% | 11.7% | 11.7% | - | 12.5% | 26.0% | 24.2% | - |
| Operating income growth (YoY) | 11.8% | - | 0.2% | 40.9% | 74.3% | - | 33.8% | 24.6% | 14.0% | - |
| Net income growth (YoY) | -1.6% | - | -9.4% | 115.1% | 63.8% | - | 32.9% | -37.0% | 5.7% | - |
| EPS growth (YoY) | 0.0% | - | -10.0% | 100.0% | 50.0% | - | 42.9% | -33.3% | 0.0% | - |
| EPS CAGR (3y) | 14.5% | - | 44.2% | 58.7% | 14.5% | - | 35.7% | 0.0% | 0.0% | - |
| EPS CAGR (5y) | 8.4% | - | 5.2% | -30.1% | -11.4% | - | 7.4% | -7.8% | - | - |
| FCF growth (YoY) | - | - | - | - | -161.4% | - | - | - | - | - |
| FCF CAGR (5y) | -13.7% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 6.8% | 7.7% | 6.9% | 17.1% | 15.9% | 15.4% | 14.8% | 14.2% | 16.2% | 17.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$75.14M totalEquipment Sales$50.25M · 66.9%
Service$24.89M · 33.1%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing VIEMED HEALTHCARE against the 5 most active filers in the same SIC group.